PIRS vs. KZR, CASI, LEXX, EQ, KRON, DARE, CLNN, NBRV, NXTC, and OCUP Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Equillium (EQ), Kronos Bio (KRON), Daré Bioscience (DARE), Clene (CLNN), Nabriva Therapeutics (NBRV), NextCure (NXTC), and Ocuphire Pharma (OCUP). These companies are all part of the "pharmaceutical preparations" industry.
Kezar Life Sciences (NASDAQ:KZR ) and Pieris Pharmaceuticals (NASDAQ:PIRS ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by company insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Kezar Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Kezar Life Sciences currently has a consensus price target of $11.00, suggesting a potential upside of 1,485.01%. Given Pieris Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Kezar Life Sciences is more favorable than Pieris Pharmaceuticals.
Kezar Life Sciences has a net margin of 0.00% compared to Kezar Life Sciences' net margin of -39.71%. Pieris Pharmaceuticals' return on equity of -47.28% beat Kezar Life Sciences' return on equity.
Pieris Pharmaceuticals received 144 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 61.37% of users gave Pieris Pharmaceuticals an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
Pieris Pharmaceuticals has higher revenue and earnings than Kezar Life Sciences. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kezar Life Sciences and Kezar Life Sciences both had 2 articles in the media. Pieris Pharmaceuticals' average media sentiment score of 1.25 beat Kezar Life Sciences' score of 0.92 indicating that Kezar Life Sciences is being referred to more favorably in the media.
Summary Kezar Life Sciences beats Pieris Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
